Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2024-12-23T12:29:40.190Z Has data issue: false hasContentIssue false

A Review of the Neurosurgical Management of Brain Metastases During Pregnancy

Published online by Cambridge University Press:  20 November 2020

Phileas J. Proskynitopoulos
Affiliation:
Department of Surgery, Division of Neurosurgery, Hamilton General Hospital, McMaster University, Hamilton, ON, Canada
Fred C. Lam*
Affiliation:
Department of Surgery, Division of Neurosurgery, Hamilton General Hospital, McMaster University, Hamilton, ON, Canada
Sunjay Sharma
Affiliation:
Department of Surgery, Division of Neurosurgery, Hamilton General Hospital, McMaster University, Hamilton, ON, Canada
Brett C. Young
Affiliation:
Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Yosef Laviv
Affiliation:
Department of Surgery, Division of Neurosurgery, Tel Aviv
Ekkehard M. Kasper*
Affiliation:
Department of Surgery, Division of Neurosurgery, Hamilton General Hospital, McMaster University, Hamilton, ON, Canada
*
Correspondence to: Ekkehard M. Kasper; Fred C. Lam, Division of Neurosurgery, Hamilton General Hospital, McMaster University, 237 Barton Street East, Hamilton, OntarioL2L 2X2, Canada. Emails: [email protected]; [email protected]
Correspondence to: Ekkehard M. Kasper; Fred C. Lam, Division of Neurosurgery, Hamilton General Hospital, McMaster University, 237 Barton Street East, Hamilton, OntarioL2L 2X2, Canada. Emails: [email protected]; [email protected]
Rights & Permissions [Opens in a new window]

Abstract:

Objective:

Patients with pregnancy-associated secondary brain tumors (PASBT) are challenging to manage. Because no guidelines for the management of such patients currently exist, we performed a systematic review of the literature using PRISMA guidelines with a discussion of management from a neurosurgeon’s perspective.

Method:

Systematic review of the literature using PRISMA guidelines from 1999 to 2018.

Results:

We identified 301 studies of which 16 publications (22 patients reporting 25 pregnancies, 20 deliveries, 5 early terminations) were suitable for final analysis. The most frequent primary cancers were breast (8/22, 36.36%), skin (6/22, 27.27%), and lung (5/22, 22.73%). Four patients (18.18%) had neurosurgical procedures during their pregnancies. Five patients (22.73%) received neurosurgical resection after their pregnancies. Nine patients (40.91%) received radiation therapy and seven patients (31.82%) received chemotherapy during pregnancy while seven patients (31.82%) received chemotherapy and radiation after pregnancy. There was 1 fetal death (5%) out of 20 healthy deliveries. Five pregnancies (20%) were terminated in the first trimester due to a need for urgent neurosurgical intervention.

Conclusion:

Management of PASBT remains a challenging issue. Maternal and fetal risks associated with surgical resection and teratogenicity due to adjuvant therapy should be discussed in the context of a multidisciplinary team. Timing of surgery and the use of systemic chemoradiation depends on the gestational age (GA) of the fetus, extent, and control of the mother’s primary and metastatic disease. Guidelines need to be established to help neuro-oncology teams safely and effectively manage this group of patients.

Résumé :

RÉSUMÉ :

Étude de la prise en charge neurochirurgicale de métastases cérébrales détectées pendant la grossesse.

Objectif :

La prise en charge de patientes enceintes chez qui l’on a diagnostiqué des tumeurs cérébrales secondaires n’est pas chose facile. Sachant qu'il n'existe actuellement aucune ligne directrice en matière de prise en charge, nous avons réalisé une revue systématique de littérature au moyen des lignes directrices PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) tout en proposant une discussion sur le sujet d’un point de vue neurochirurgical.

Méthode :

Une revue systématique de littérature au moyen des lignes directrices PRISMA, et ce, de 1999 à 2018.

Résultats :

Au total, nous avons identifié 301 études. De ce nombre, 16 d’entre elles ont pu se prêter à une analyse finale. À noter que ces 16 études incluaient 22 patientes ayant rapporté 25 grossesses, 20 accouchements et 5 interruptions de grossesse prématurées. Les cancers primitifs les plus fréquents étaient ceux du sein (8/22, soit 36,36 %), de la peau (6/22, soit 27,27 %) et du poumon (5/22, soit 22,73 %). Soulignons que 4 patientes (18,18 %) ont subi des interventions neurochirurgicales en cours de grossesse tandis que 5 d’entre elles (22,73 %) ont bénéficié de résection neurochirurgicale après leur accouchement. De plus, 9 patientes (40,91 %) ont reçu des traitements de radiothérapie, 7 d’entre elles (31,82 %) ont reçu des traitements de chimiothérapie en cours de grossesse et 7 autres (31,82 %) ont reçu à la fois des traitements de radiothérapie et de chimiothérapie à la suite de leur accouchement. Sur 20 accouchements de fœtus jugés en bonne santé, on a constaté un décès (5 %). Enfin, 5 grossesses, soit 20 %, ont dues être interrompues lors du premier trimestre en raison d’une intervention neurochirurgicale urgente.

Conclusion :

La prise en charge de patientes enceintes chez qui l’on a diagnostiqué des tumeurs cérébrales secondaires demeure un enjeu compliqué à aborder. Les risques associés à la résection chirurgicale et à la tératogénicité de la chimiothérapie adjuvante auxquels font face mères et fœtus devraient être discutés dans le cadre d’une équipe multidisciplinaire. Le moment choisi pour une intervention chirurgicale et l’utilisation systématique de chimio-radiation dépendent entre autres de l’âge gestationnel du fœtus mais aussi de l’étendue et du contrôle de la maladie métastatique primitive de la mère. Chose certaine, des lignes directrices devraient être établies en vue d’aider les équipes de neuro-oncologie à prendre en charge ces patientes de manière sûre et efficace.

Type
Original Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2020. Published by Cambridge University Press on behalf of The Canadian Journal of Neurological Sciences Inc.

Introduction

There has been a trend toward delaying motherhood in developed countries, resulting in an average age of 26.3 years for mothers delivering their first-born child in the USA in 2014. Reference Bichell6 Unfortunately, this delay in motherhood has led to an overlap with the period of increasing natural incidences of certain cancers. At present, the cumulative incidence of cancers in pregnant women has been estimated to be at around 1 in 1000–2000 pregnancies, Reference Aronowitz3 further creating a unique and challenging clinical scenario of pregnancy-associated secondary brain tumors (PASBT). Among these, there has been an increased incidence of breast, melanoma, and lung cancer, all of which have propensities to metastasize to the brain. Reference Ostrom, Wright and Barnholtz-Sloan35

There are obvious risks to the fetus when treating expectant mothers diagnosed with cancer using chemoradiation. Beyond that, there are elevated anesthesia risks and other comorbidities associated with many non-obstetrics-related surgical procedures when performed during pregnancy. Reference Cordeiro and Gemignani12,Reference Greskovich and Macklis14,Reference Morris28 It is noteworthy that there are currently no guidelines regarding the neurosurgical treatment of PASBT. To address this void, we performed a systematic review of the literature with a focus on PASBT to coalesce common and unique challenges in this setting and to discuss key aspects in managing these patients from a neurosurgeon’s perspective.

Materials and Methods

Data Sources

A PRISMA-guided literature search in MEDLINE (PubMed) was conducted using the search phrases “brain”, “intracranial”, “intracerebral”, “cancer”, “metastasis”, “pregnancy”.

An additional search was conducted using Google Scholar to avoid missing articles that may have lacked one or more of the above search terms.

Search Criteria

Studies had to meet the following criteria to be included in our analysis: (1) Published in the MRI era between January 1990 and August 2018; (2) English language; (3) Human subjects; and (4) Peer-reviewed publications. A PRISMA workflow diagram is provided in Figure 1.

Figure 1: PRISMA 2009 flow diagram.

Data Extraction

The following information had to be available in selected articles and was extracted from all suitable publications identified in our PubMed search: (a) Classification of primary malignancy; (b) Description of brain metastases; (c) Diagnostic method and criteria for detection of brain metastases; (d) Information regarding pregnancy status and management, including outcome; (e) Description of details regarding treatment of brain metastases during pregnancy; (f) Age of the mother; (g) Gestational age (GA) of the fetus at diagnosis and delivery; (h) Method of delivery.

Results

A total of 301 studies were retrieved after the application of our PRISMA algorithm (Figure 1). Of these, 16 fulfilled all inclusion criteria, and 2 studies presented more than 1 case. This resulted in a pooled cohort of 22 cases of PASBT, which we included in our final analysis. Individual cases and reports are summarized in detail in Table 1.

Table 1: Summary table of relevant cases of PASBT identified through our PRISMA search

C-section = cesarean section; CKRS = CyberKnife Radiosurgery; GA = gestational age; GKRS = Gamma Knife Radiosurgery; ICP = intracranial pressure; SRS = stereotactic radiosurgery; WBRT = whole-brain radiotherapy; 5-FU = 5-Fluorouracil.

Tumor Diagnoses

Eight of the 22 patients (36.36%) had breast cancer: Six with intraductal/infiltrative breast cancer and two with triple-negative breast cancer. Six patients (27.27%) presented with a primary skin tumor: three of those were classified as superficial spreading melanoma, and three as malignant melanomas. Five patients (22.73%) had lung cancer and the remaining three patients (13.64%) had various pathologies, including one Wilms’ tumor; one follicular thyroid carcinoma; and one primary mediastinal large B-cell non-Hodgkin’s lymphoma.

Chemotherapy Only

One patient presenting with spine and brain metastases due to large B-cell non-Hodgkin’s lymphoma at 18 weeks GA was treated with chemotherapy alone during the pregnancy. Reference Kumagai, Koishi, Takahashi and Suzuki21

Radiation Therapy Only

Four patients (18.18%) received single modality radiotherapy for the treatment of their brain metastases: three patients received stereotactic radiosurgery (SRS) during their pregnancy at 24 weeks GA, Reference Pages, Robert and Thomas36 25 weeks GA Reference Yu, Jozsef, Apuzzo, MacPherson and Petrovich50 and 26 weeks GA. Reference Verheecke, Halaska and Lok47 One patient received whole-brain radiotherapy (WBRT) after her elective C-section at 30 weeks GA. Reference Verheecke, Halaska and Lok47

Neurosurgical Procedure Only

Three patients (13.64%) had neurosurgical interventions after their pregnancies: One patient had an insertion of a ventriculoperitoneal (VP) shunt after early termination of her pregnancy at 9 weeks GAReference Goutham, Kumar, Anil, Peter, Ravi and Chakravorthy13; Two patients had surgical resection of their tumors after successful term deliveries.Reference Huang, Cheng, Chen, Hsu, Liu and Chen18,Reference Okuda, Yamamoto, Matsuo, Kataoka and Kitawaki34

Chemoradiation Only

Seven patients (31.82%) received combination chemotherapy and radiation. Five patients received chemotherapy and radiation both during and after their pregnancies, Reference Gupta, Jain and McDunn15,Reference Holzmann, Kropfmuller and Schinko17,Reference Magne, Marcie, Pignol, Casagrande and Lagrange23,Reference Pages, Robert and Thomas36,Reference Verheecke, Halaska and Lok47 while two patients received treatments after their pregnancies. Reference Okuda, Yamamoto, Matsuo, Kataoka and Kitawaki34,Reference Trinca, Inacio, Timoteo and Dinis46

Combined Neurosurgical Intervention and Chemoradiation Therapy

Four patients had combined interventions: One patient had chemotherapy during her pregnancy followed by neurosurgical resection and chemoradiation after successful delivery of her child Reference Mandrawa, Stewart, Fabinyi and Walker24 ; the second patient received surgical resection of her metastasis during pregnancy followed by WBRT and chemotherapy after successful delivery of her child Reference Wang, Cui, Yan, Jin and Hong49 ; the third patient received chemoradiation prior to neurosurgical resection followed by further resection at the time of recurrence and WBRT during her pregnancy with the successful delivery of a healthy fetus. Reference Stovall, Blackwell and Cundiff42 Timing of the above interventions with maternal/fetal outcomes is summarized in Table 1.

Discussion

The detection of brain metastasis during pregnancy is a rare occurrence. However, the risks surrounding the treatment of the mother’s primary tumor and metastatic disease have to be balanced against maintaining the health and viability of the fetus and those competing treatment goals pose significant challenges to the neurosurgeon.

It is estimated that 20% of cancer patients will develop brain metastases. Reference Achrol, Rennert and Anders1,Reference Nayak, Lee and Wen30 Of these, lung (20–56%), breast (5–20%), and melanoma (7–16%) most commonly metastasize to the brain with the prevalence of renal cell carcinoma and colorectal cancer on the rise. Reference Achrol, Rennert and Anders1,Reference Barnholtz-Sloan, Sloan, Davis, Vigneau, Lai and Sawaya5 Lung cancer is the most frequent to metastasize to the brain irrespective of gender, but breast cancer metastases are the most common occurrence in women. Reference Achrol, Rennert and Anders1 Risk of brain metastases also varies with age and the type of primary, with breast cancer brain metastases being reported as highest in younger patients (20–39 years of age), lung cancer brain metastases the highest in middle-aged patients (40–49 years of age), and melanoma, renal cell carcinoma, and colorectal cancer brain metastases highest in older patients (50–59 years of age). Reference Barnholtz-Sloan, Sloan, Davis, Vigneau, Lai and Sawaya5,Reference Holzmann, Kropfmuller and Schinko17,Reference Hung, Liu and Shiau19 Interestingly, the increased risk of brain metastases in patients younger than 35 years of age was independent of cancer subtype, however, triple-negative or HER2-positive breast cancer subtypes were associated with a higher risk of brain metastases in patients older than 35 years of age. Reference Achrol, Rennert and Anders1 These epidemiologic findings highlight the need for neurosurgical guidelines for the management of patients with PASBT, as the neurological disease causes up to 25% mortality in patients with brain metastases. Reference Neal, Chan and Lucas31,Reference Tabouret, Chinot, Metellus, Tallet, Viens and Goncalves44

Guiding Algorithms

Safe Dosing of Radiation Therapy for Brain Metastases During Pregnancy

In a general cancer patient population of male and female nonpregnant individuals, there is Level 1 evidence that surgery followed by WBRT is recommended as first-line treatment in all patients with single brain metastases with a favorable performance status and limited extracranial disease, as outlined in the 2019 guidelines put out by the Congress of Neurological Surgeons. Reference Nahed, Alvarez-Breckenridge and Brastianos29 However, SRS to the tumor bed has recently been shown to have equivalent survival outcomes and just slightly inferior local control rates, and can thus be used as an effective alternative to WBRT (median survival of SRS = 12.2 months vs. WBRT = 11.6 months). Reference McTyre, Johnson and Ruiz27 This may be an appealing treatment alternative in this setting to attenuate neurocognitive deficits associated with WBRT, especially poignant in young expectant mothers with well-controlled systemic disease. Reference Brown, Ballman and Cerhan8 Modern shielding techniques can scatter radiation and shield the fetus from the adverse effects of WBRT, including mental retardation, organ malformations, and radiation-induced childhood malignancies. Reference Greskovich and Macklis14,Reference Magne, Marcie, Pignol, Casagrande and Lagrange23,Reference Parsai, Nalk, Djemil and Chao37,Reference Yu, Jozsef, Apuzzo, MacPherson and Petrovich50

Timing of Neurosurgical Intervention During Pregnancy

Of the 11 cases requiring neurosurgical intervention, only 1 case required emergent craniotomy to alleviate increased intracranial pressure due to tumor mass effect. Both the mother and her fetus survived the surgery and the fetus was subsequently delivered via cesarean section at 38 weeks GA. Reference Wang, Cui, Yan, Jin and Hong49 Surgery should be delayed if possible until after the first trimester to minimize miscarriage risk, which can be as high as 10.5%. Reference Cohen-Gadol, Friedman, Friedman, Tubbs, Munis and Meyer10,Reference Cohen-Kerem, Railton, Oren, Lishner and Koren11 However, it is generally considered to be safe during the second and third trimesters with recommended dosimetry guidelines for safety. Reference Greskovich and Macklis14,Reference Paulsson, Braunstein and Phillips38,Reference Stovall, Blackwell and Cundiff42,Reference Yu, Jozsef, Apuzzo, MacPherson and Petrovich50

To compare our study results to a larger patient population, we turned to a retrospective cohort study of pregnancy-related hospitalizations between 1998 and 2009 gathered from the Nationwide Inpatient Sample (NISQIP), a database of nonfederal US hospitalizations. Here, a recent study identified 19.75 million pregnancy-associated admissions, 397 associated with malignant brain tumors, including 165 associated deliveries (44%). Reference Terry, Barker and Leffert45 Patients with malignant tumors had more pregnancy complications including preterm labor, intrauterine growth restriction, and stillbirths. The rate of craniotomies for malignant tumors was 31.4% although the study did not differentiate between primary or metastatic brain malignancies. This was much lower than the 50% rate of craniotomies from our systematic review, however, this may be due to a lower rate of metastatic brain tumors in the former study. There was also a higher rate of C-sections amongst pregnant women with malignant tumors compared to the normal population, similar to the 65% of cases that required C-sections in our systematic review.

Our systematic review also identified one patient who required VP shunting for hydrocephalus. Reference Goutham, Kumar, Anil, Peter, Ravi and Chakravorthy13 A retrospective series of 77 pregnancies in 37 women with VP shunts showed that rates of shunt revisions were 10 times higher during pregnancy or the following 6 months ensuing likely due to raised intra-abdominal pressures causing distal shunt failure. Reference Bradley, Liakos and McAllister7 This had led some neurosurgeons to consider ventriculoatrial (VA) shunts for pregnant women, but VA shunts carry significant risks of arrhythmias, infection, valvular dysfunction, and high morbidity associated with revisions. The neurosurgeon should, therefore, closely monitor the pregnant patient for signs and symptoms of shunt failure in the peripartum and postpartum periods. Reference Tabouret, Chinot, Metellus, Tallet, Viens and Goncalves44

Timing of Use of Antileptic Drugs During Pregnancy

Important to the neurosurgical management of patients with supratentorial tumors is the use of antiepileptic drugs (AEDs) to manage symptomatic lesions presenting with seizures. Older generation AEDs such as valproic acid and phenobarbital have been associated with increased rates of teratogenicity and congenital malformations (up to 9.3% and 5.5%, respectively) such as cardiac defects, cleft lip/palate, neural tube defects, and dysmorphic syndromes. Reference Hernandez-Diaz, Smith and Shen16 However, newer agents such as lamotrigine and levetiracetam (currently, the most commonly used AED in neurosurgery) have improved safety profiles for use in pregnancy with much lower reported rates of congenital malformations between 0.7% and 2.4%. Reference Hernandez-Diaz, Smith and Shen16,Reference Mawhinney, Craig and Morrow25 Doses of AEDs should be tapered to the minimally effective dose to achieve seizure control and used for the shortest period of time possible during pregnancy. Reference Hernandez-Diaz, Smith and Shen16

Surgical Considerations of the Pregnant Patient During Neurosurgical Procedures

Unique challenges exist during the positioning of the patient for non-obstetric surgeries during pregnancy. Prevention of positioning injuries to mother and fetus needs to be observed and the operating table should be centered and parallel to the longest wall in the room to minimize the need for relocation prior to the patient entering the operating room. Reference Barnett, Bartalot, Nezhat, Nezhat, Kavic, Lanzafame, Lindsay and Polk4 When possible, the patient should be maintained in the left lateral recumbent position using a positioning wedge to avoid a flat supine position once transferred onto the operating table with attention to the application of non-constricting safety straps to not harm, yet prevent the patient from falling off the table. 2 A uterine displacing wedge or chests rolls should be used to reduce pressure from the pregnant uterus on the vena cava and straps across the chest are discouraged to avoid restricting respiratory effectiveness. Reference Carzo, Viveiro, Rothrock and McEwen9 Pressure points on the mother’s body should be well padded to prevent ulcers and peripheral neuropathies during surgery. Hypothermia should be carefully avoided (e.g. with the use of a warming blanket). Intraoperative electronic fetal monitoring past 26 weeks GA may be applied if the fetus is viable, if the monitor does not physically interfere with the procedure, if an obstetrician is available with prior consent obtained to perform an emergency C-section for fetal distress, and if the type of surgery is safe for the interruption to perform an emergency delivery if warranted. Reference Barnett, Bartalot, Nezhat, Nezhat, Kavic, Lanzafame, Lindsay and Polk4,Reference Reitman and Flood40

Anesthetic Considerations for the Pregnant Patient

Special anesthetic considerations are also required for non-obstetric procedures during pregnancy in order to avoid the complications of fetal loss, premature labor, and delivery. Cardiopulmonary changes in maternal physiology during pregnancy can lead to unintended general hypotension, difficult laryngeal intubation with potential airway edema, hypoxemia, and increased uterine irritability leading to preterm labor. Reference Nejdlova and Johnson32 The mother should be informed regarding the low risk of teratogenicity associated with anesthetic agents and a neonatal team should be available and present should premature labor be anticipated. Regional anesthesia is preferred over general anesthesia where it is feasible to minimize drug exposure to the fetal and allow the mother to maintain her own airway, however, there is a lack of evidence supporting these claims in the form of randomized clinical trials.

In the case of neurosurgical procedures, general anesthesia can rarely be avoided. Reference Ni Mhuireachtaigh and O’Gorman33 Maintenance of PCO2 during the surgery can also be challenging as ventilation should be aimed to keep levels within the normal range of pregnancy, however, hyperventilation may be required to decrease central vasodilation as a means of lowering intracranial pressures during tumor resection. Extubation should be performed with a full anesthetic reversal and preferably in the lateral position to avoid aspiration. Reference Sharma, Nguyen, Lozen and Mueller41

Suggested Algorithm for the Treatment of Brain Metastases in the Pregnant Patient

We recently published a case series reviewing the surgical management of 104 meningioma patients during pregnancy and proposed an algorithm dividing the date of diagnosis with GA of the fetus for the surgical management of these patients into two groups. Reference Laviv, Bayoumi, Mahadevan, Young, Boone and Kasper22 Using a similar algorithm based on studies in our systematic review and current literature, we propose dividing patients with PASBT into three groups in order to guide the timing of neurosurgical interventions:

  1. 1) Group A – Patients at ≤ 13 weeks GA

    • Surgery and/or systemic chemotherapy or radiotherapy should be delayed past the first and second trimesters if possible to prevent teratogenic effects of anesthetic drugs, chemotherapy, and radiation, as well as premature labor caused by anesthesia-induced hypotension to the placenta and uterus.

    • If patients require radiation therapy, SRS is preferred over WBRT to reduce long-term neurocognitive dysfunction to the mother and congenital malformations to the fetus. Body shielding should be used to minimize radiation exposure to the fetus.

    • If surgery and/or chemoradiation cannot be avoided, then a frank discussion should be had with the patient explaining adverse effects to the fetus and options including early termination of pregnancy.

    • Any practical aspects of survival intervention (positioning/pinning) are usually not compromised yet in this patient subgroup, as the pregnant uterus remains small and patients can even be positioned prone without significant concerns.

  2. 2) Group B – Patients between 13 and 26 weeks GA

    • The same algorithm as in Group A can be applied to Group B patients but if the patient is diagnosed or becomes symptomatic at around 26 weeks GA, the option of C-section to deliver the fetus with support in a neonatal intensive care unit should be presented to the patient prior to treatment for her symptomatic brain metastases. Here, and only if circumstances allow, the goal for initial treatment would remain to bring the baby as close to 30 weeks of GA as possible, since the relative risk reduction of infant mortality per week is greatest before that date. Reference Szuflita, Boulter, Gihooly, Neal, Nezhat, Kavic, Lanzafame, Lindsay and Polk43

    • If surgical intervention is required, the left lateral decubitus or supine position is the preferred way to perform surgery at this stage.

  3. 3) Group C – Patients at ≥ 26 weeks GA

    • Symptomatic patients requiring surgery and/or chemoradiation should be presented with the delivery of their fetus via C-section or forceps-assisted delivery (to avoid raised intracranial pressures that may be associated with straining during labor) prior to their neurosurgical intervention.

    • Late into the third trimester, the teratogenic effects of chemotherapy and radiation exposure are much lessened and may allow for treatment of the mother without needing to deliver the fetus but risks need to be discussed with the mother.

    • As above, if surgical intervention is required, the left lateral decubitus or supine position is the preferred way to perform surgery at this stage.

Finally, current advances in targeted therapies for the treatment of breast, lung, and melanoma cancers may dramatically change the way we approach the treatment of PASBT in the future. While there remains a paucity of information regarding the long-term teratogenicity of targeted therapies, the HER2-neu receptor antagonist trastuzumab has been used for the treatment of breast cancer during pregnancy. Reference Mandrawa, Stewart, Fabinyi and Walker24 The BRAF inhibitor dabrafenib is classified as a category D agent and therefore contraindicated for the treatment of metastatic melanoma during pregnancy. Reference McGettigan26 Similarly, there is a lack of data pertaining to fetal safety for the EGFR inhibitor erlotinib, currently, the standard of care treatment for EGFR-mutated lung cancer in the USA, Reference Ji, Schwartz, Hartford, Ramsey, Phillips and Verschraegen20 hence conventional standard chemotherapy remains recommended in the treatment of pregnant patients with lung cancer. We eagerly await longitudinal data using immunotherapies and other novel modalities for the treatment of brain metastases, which may be added to increase the neurosurgeon’s armamentarium in managing PABST. Reference Achrol, Rennert and Anders1

Conclusion

In conclusion, neurosurgical management of PASBT is a challenging problem and should involve a multidisciplinary team of neuro-oncologists, anesthesiologists, obstetricians, neonatologists, and ethicists in order to fully inform the mother of the risks to herself and her unborn fetus. The increasing ability of systemic targeted therapies to effectively control a patient’s primary disease combined with research into understanding the process of brain metastasis formation will hopefully lead to novel therapies, which are both effective and safe for the health and viability of the mother and fetus.

Acknowledgements

We would like to thank the administrative staff in the Division of Neurosurgery at McMaster University Faculty of Health Sciences, in particular Ms. Kim Morris and Ms. Christina Vandervlist for their assistance in the final submission process of this manuscript.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Author Contributions

P.J.P, F.C.L. designed, wrote, and analyzed the data. S.S., B.C.Y., and Y.L. edited the manuscript. E.M.K. supervised, designed, and edited the manuscript.

Footnotes

Authors contributed equally to this work.

References

Achrol, AS, Rennert, RC, Anders, C, et al. Brain metastases. Nat Rev Dis Primers. 2019;5:5. doi: 10.1038/s41572-018-0055-y CrossRefGoogle ScholarPubMed
AORN AORN Guideline for Positioning the Patient. Standards, recommended practices, and guidelines. AORN Inc, Denver; 2007.Google Scholar
Aronowitz, RA, editor. Unnatural history: breast cancer and American society. Cambridge: Cambridge University Press; 2007.Google Scholar
Barnett, V, Bartalot, AN, Nezhat, CH Operating room setup and patient positioning for non-obstetric surgery. In: Nezhat, CH, Kavic, MS, Lanzafame, RJ, Lindsay, MK, Polk, TM, editors. Non-obstetric surgery during pregnancy. Cham: Springer; 2019. pp. 7183.CrossRefGoogle Scholar
Barnholtz-Sloan, JS, Sloan, AE, Davis, FG, Vigneau, FD, Lai, P, Sawaya, RE Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22:2865–72. doi: 10.1200/JCO.2004.12.149 CrossRefGoogle ScholarPubMed
Bichell, RE Average age of first-time moms keeps climbing in the U.S.; 2016.Google Scholar
Bradley, NK, Liakos, AM, McAllister, JP, 2nd, et al. Maternal shunt dependency: implications for obstetric care, neurosurgical management, and pregnancy outcomes and a review of selected literature. Neurosurgery 1998;43:448–60; discussion 460–441. doi: 10.1097/00006123-199809000-00030 CrossRefGoogle Scholar
Brown, PD, Ballman, KV, Cerhan, JH, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18:1049–60. doi: S1470-2045(17)30441-2 [pii]CrossRefGoogle ScholarPubMed
Carzo, SA, Viveiro, JH Gynecologic and obstetric surgery. In: Rothrock, J, McEwen, D, editors. Alexander’s care of the patient in surgery. 15th ed. St. Louis: Mosby/Elsevier; 2015. pp. 405–60.Google Scholar
Cohen-Gadol, AA, Friedman, JA, Friedman, JD, Tubbs, RS, Munis, JR, Meyer, FB Neurosurgical management of intracranial lesions in the pregnant patient: a 36-year institutional experience and review of the literature. J Neurosurg. 2009;111:1150–57. doi: 10.3171/2009.3.JNS081160 CrossRefGoogle ScholarPubMed
Cohen-Kerem, R, Railton, C, Oren, D, Lishner, M, Koren, G Pregnancy outcome following non-obstetric surgical intervention. Am J Surg. 2005;190:467–73. doi: S0002-9610(05)00501-5 [pii]CrossRefGoogle ScholarPubMed
Cordeiro, CN, Gemignani, ML Breast cancer in pregnancy: avoiding fetal harm when maternal treatment is necessary. Breast J. 2017;23:200–5. doi: 10.1111/tbj.12780 CrossRefGoogle ScholarPubMed
Goutham, C, Kumar, JP, Anil, P, Peter, SN, Ravi, R, Chakravorthy, VM Malignant course of a metastatic melanoma during pregnancy: a case report. World J Oncol. 2011;2:7982. doi: 10.4021/wjon285w Google ScholarPubMed
Greskovich, JF Jr., Macklis, RM Radiation therapy in pregnancy: risk calculation and risk minimization. Semin Oncol. 2000;27:633–45.Google ScholarPubMed
Gupta, S, Jain, P, McDunn, S Breast cancer with brain metastases in pregnancy. J Community Support Oncol. 2014;12:378–80.Google ScholarPubMed
Hernandez-Diaz, S, Smith, CR, Shen, A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012;78:1692–99. doi: 10.1212/WNL.0b013e3182574f39 CrossRefGoogle ScholarPubMed
Holzmann, K, Kropfmuller, R, Schinko, H, et al. Lung cancer in pregnancy. Wien Klin Wochenschr. 2015;127:639–44. doi: 10.1007/s00508-015-0726-6 CrossRefGoogle ScholarPubMed
Huang, TC, Cheng, YK, Chen, TW, Hsu, YC, Liu, EW, Chen, HH A ‘silent’ skull metastatic follicular thyroid carcinoma mimicking as a benign scalp tumor in a pregnant woman. Endocrinol Diabetes Metab Case Rep. 2017:16-0100. doi: 10.1530/EDM-16-0100.Google ScholarPubMed
Hung, MH, Liu, CY, Shiau, CY, et al. Effect of age and biological subtype on the risk and timing of brain metastasis in breast cancer patients. PLoS One 2014;9:e89389. doi: 10.1371/journal.pone.0089389 CrossRefGoogle ScholarPubMed
Ji, Y, Schwartz, J, Hartford, A, Ramsey, J, Phillips, J, Verschraegen, C Successful treatment of non-small cell lung cancer with erlotinib throughout pregnancy. JAMA Oncol. 2015;1:838–40. doi: 10.1001/jamaoncol.2015.1300 CrossRefGoogle ScholarPubMed
Kumagai, M, Koishi, W, Takahashi, H, Suzuki, K Perioperative management of a pregnant patient with mediastinal tumor complicated by tuberculosis. J A Clin Rep. 2017;3:66. doi: 10.1186/s40981-017-0136-z CrossRefGoogle ScholarPubMed
Laviv, Y, Bayoumi, A, Mahadevan, A, Young, B, Boone, M, Kasper, EM Meningiomas in pregnancy: timing of surgery and clinical outcomes as observed in 104 cases and establishment of a best management strategy. Acta Neurochir (Wien). 2018;160:1521–29. doi: 10.1007/s00701-017-3146-8 CrossRefGoogle ScholarPubMed
Magne, N, Marcie, S, Pignol, JP, Casagrande, F, Lagrange, JL Radiotherapy for a solitary brain metastasis during pregnancy: a method for reducing fetal dose. Br J Radiol. 2001;74:638–41. doi: 10.1259/bjr.74.883.740638 CrossRefGoogle ScholarPubMed
Mandrawa, CL, Stewart, J, Fabinyi, GC, Walker, SP A case study of trastuzumab treatment for metastatic breast cancer in pregnancy: fetal risks and management of cerebral metastases. Aust N Z J Obstet Gynaecol. 2011;51:372–76. doi: 10.1111/j.1479-828X.2011.01314.x CrossRefGoogle ScholarPubMed
Mawhinney, E, Craig, J, Morrow, J, et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology 2013;80:400–5. doi: 10.1212/WNL.0b013e31827f0874 CrossRefGoogle ScholarPubMed
McGettigan, S Dabrafenib: a new therapy for use in BRAF-mutated metastatic melanoma. J Adv Pract Oncol. 2014;5:211–15.Google ScholarPubMed
McTyre, ER, Johnson, AG, Ruiz, J, et al. Predictors of neurologic and nonneurologic death in patients with brain metastasis initially treated with upfront stereotactic radiosurgery without whole-brain radiation therapy. Neuro Oncol. 2017;19:558–66. doi: 10.1093/neuonc/now184 Google ScholarPubMed
Morris, MC Obstetric anesthesia. Philadelphia: JB Lippincott Co; 1993.Google Scholar
Nahed, BV, Alvarez-Breckenridge, C, Brastianos, PK, et al. Congress of neurological surgeons systematic review and evidence-based guidelines on the role of surgery in the management of adults with metastatic brain tumors. Neurosurgery 2019;84:E15255. doi: 10.1093/neuros/nyy542 CrossRefGoogle ScholarPubMed
Nayak, L, Lee, EQ, Wen, PY Epidemiology of brain metastases. Curr Oncol Rep. 2012;14:4854. doi: 10.1007/s11912-011-0203-y CrossRefGoogle ScholarPubMed
Neal, MT, Chan, MD, Lucas, JT Jr., et al. Predictors of survival, neurologic death, local failure, and distant failure after gamma knife radiosurgery for melanoma brain metastases. World Neurosurg. 2014;82:1250–55. doi: 10.1016/j.wneu.2013.02.025 CrossRefGoogle ScholarPubMed
Nejdlova, M, Johnson, T Anaesthesia for non-obstetric procedures during pregnancy. Continuing Education in Anaesthesia, Critical Care & Pain 2012;12:203–6.CrossRefGoogle Scholar
Ni Mhuireachtaigh, R, O’Gorman, DA Anesthesia in pregnant patients for nonobstetric surgery. J Clin Anesth. 2006;18:6066. doi: S0952-8180(05)00335-1 [pii]CrossRefGoogle ScholarPubMed
Okuda, T, Yamamoto, S, Matsuo, S, Kataoka, H, Kitawaki, J Metastasis of pregnancy-associated breast cancer (suspected to be hereditary breast and ovarian cancer) to the brain, diagnosed at 18 weeks’ gestation: a case report and review of the literature. Case Rep Obstet Gynecol. 2016;2016:9813253. doi: 10.1155/2016/9813253 Google ScholarPubMed
Ostrom, QT, Wright, CH, Barnholtz-Sloan, JS Brain metastases: epidemiology. Handb Clin Neurol. 2018;149:2742. doi: B978-0-12-811161-1.00002-5 [pii]CrossRefGoogle ScholarPubMed
Pages, C, Robert, C, Thomas, L, et al. Management and outcome of metastatic melanoma during pregnancy. Br J Dermatol. 2010;162:274–81. doi: 10.1111/j.1365-2133.2009.09240.x CrossRefGoogle ScholarPubMed
Parsai, S, Nalk, M, Djemil, T, Chao, S Whole-brain radiation therapy in pregnant patients with brain metastases: risks of ionizing radiation exposure to the fetus. Appl Rad Oncol. 2015:40A40D.Google Scholar
Paulsson, AK, Braunstein, S, Phillips, J, et al. Patient-specific fetal dose determination for multi-target gamma knife radiosurgery: computational model and case report. Cureus 2017;9:e1527. doi: 10.7759/cureus.1527 Google ScholarPubMed
Practice ACoO. ACOG committee opinion No. 474: non-obstetric surgery during pregnancy. Obstet Gynecol. 2011;117:420421.CrossRefGoogle Scholar
Reitman, E, Flood, P Anaesthetic considerations for non-obstetric surgery during pregnancy. Br J Anaesth. 2011;107(Suppl 1):i7278. doi: 10.1093/bja/aer343 CrossRefGoogle ScholarPubMed
Sharma, A, Nguyen, HS, Lozen, A, Mueller, W Brain metastases from breast cancer during pregnancy. Surg Neurol Int. 2016;7:S603606. doi: 10.4103/2152-7806.189730 CrossRefGoogle ScholarPubMed
Stovall, M, Blackwell, CR, Cundiff, J, et al. Fetal dose from radiotherapy with photon beams: report of AAPM radiation therapy committee task group No. 36. Med Phys. 1995;22:6382. doi: 10.1118/1.597525 CrossRefGoogle ScholarPubMed
Szuflita, NS, Boulter, JH, Gihooly, JE, Neal, CJ Neurosurgery during pregnancy. In: Nezhat, CH, Kavic, M, Lanzafame, R, Lindsay, M, Polk, T, editors. Non-obstetric surgery during pregnancy. Cham: Springer; 2019. pp 211–24.CrossRefGoogle Scholar
Tabouret, E, Chinot, O, Metellus, P, Tallet, A, Viens, P, Goncalves, A Recent trends in epidemiology of brain metastases: an overview. Anticancer Res. 2012;32:4655–62.Google ScholarPubMed
Terry, AR, Barker, FG, 2nd, Leffert, L, et al. Outcomes of hospitalization in pregnant women with CNS neoplasms: a population-based study. Neuro Oncol. 2012;14:768–76. doi: 10.1093/neuonc/nos078 CrossRefGoogle ScholarPubMed
Trinca, F, Inacio, M, Timoteo, T, Dinis, R Triple-negative breast cancer with brain metastasis in a pregnant woman. BMJ Case Rep. 2017;2017:bcr2016218657. doi: 10.1136/bcr-2016-218657 CrossRefGoogle ScholarPubMed
Verheecke, M, Halaska, MJ, Lok, CA, et al. Primary brain tumours, meningiomas and brain metastases in pregnancy: report on 27 cases and review of literature. Eur J Cancer 2014;50:1462–71. doi: 10.1016/j.ejca.2014.02.018 CrossRefGoogle ScholarPubMed
Vetter, G, Zimmermann, F, Bruder, E, Schulzke, S, Hosli, I, Vetter, M Aggressive breast cancer during pregnancy with a rare form of metastasis in the maternal placenta. Geburtshilfe Frauenheilkd. 2014;74:579–82. doi: 10.1055/s-0034-1368181 Google ScholarPubMed
Wang, Y, Cui, J, Yan, X, Jin, R, Hong, X Alveolar soft part sarcoma with multiple brain and lung metastases in pregnancy: a case report and literature review. Medicine (Baltimore) 2017;96:e8790. doi: 10.1097/MD.0000000000008790 CrossRefGoogle ScholarPubMed
Yu, C, Jozsef, G, Apuzzo, ML, MacPherson, DM, Petrovich, Z Fetal radiation doses for model C gamma knife radiosurgery. Neurosurgery 2003;52:687–93; discussion 693. doi: 10.1227/01.neu.0000048479.23069.24 CrossRefGoogle Scholar
Figure 0

Figure 1: PRISMA 2009 flow diagram.

Figure 1

Table 1: Summary table of relevant cases of PASBT identified through our PRISMA search